Oseltamivir (Tamiflu) 💊
Irish hospital reference for oseltamivir (Tamiflu): who to treat under the 2026 HSE influenza antiviral guidance, adult dose, renal dosing, dialysis, and post-exposure prophylaxis.
💡 Who to treat
- Treat suspected or confirmed influenza if the patient is admitted because of it, or has severe complications or progressive illness.
- Start straight away. Do not wait for the swab, and still treat if more than 48 hours from onset.
- Finish the course even if the first swab says not detected, unless another diagnosis explains the illness.
- Non-severe influenza: antivirals are not recommended, even in high-risk groups. Explain the signs of severe influenza and when to seek help.
- Vaccination does not exclude influenza. Apply infection prevention and control precautions.
Adult dose (13 years and over, over 40 kg)
Treatment
- Dose
- 75 mg PO or NG
- Frequency
- BD
- Duration
- 5 days
- Notes
- Critically ill: at least 10 days may be needed. No response by day 5: resistance testing (NVRL)
Treatment, immunocompromised
- Dose
- 75 mg PO or NG
- Frequency
- BD
- Duration
- 10 days
- Notes
- Severely immunocompromised: send influenza A subtyping to NVRL at the start
Post-exposure prophylaxis
- Dose
- 75 mg PO
- Frequency
- OD
- Duration
- 10 days after last exposure
- Notes
- Start within 48 hours of exposure. Later only on specialist advice
Child 1 year and over
- Dose
- 10–15 kg 30 mg, >15–23 kg 45 mg, >23–40 kg 60 mg
- Frequency
- BD (OD for prophylaxis)
- Duration
- As above
- Notes
- 13 and over but 40 kg or less: 60 mg. Under 1 year (36 weeks post-conceptual age or more): 3 mg/kg. Check with paediatrics
| Use | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Treatment | 75 mg PO or NG | BD | 5 days | Critically ill: at least 10 days may be needed. No response by day 5: resistance testing (NVRL) |
| Treatment, immunocompromised | 75 mg PO or NG | BD | 10 days | Severely immunocompromised: send influenza A subtyping to NVRL at the start |
| Post-exposure prophylaxis | 75 mg PO | OD | 10 days after last exposure | Start within 48 hours of exposure. Later only on specialist advice |
| Child 1 year and over | 10–15 kg 30 mg, >15–23 kg 45 mg, >23–40 kg 60 mg | BD (OD for prophylaxis) | As above | 13 and over but 40 kg or less: 60 mg. Under 1 year (36 weeks post-conceptual age or more): 3 mg/kg. Check with paediatrics |
Renal dosing (CrCl)
- If you only have an eGFR, dose on it. Do not delay the first dose. Use the Creatinine clearance calculator when you can.
- No change for liver impairment or in older adults with normal renal function.
>60
- Treatment
- 75 mg BD
- Prophylaxis
- 75 mg OD
31–60
- Treatment
- 30 mg BD
- Prophylaxis
- 30 mg OD
11–30
- Treatment
- 30 mg OD
- Prophylaxis
- 30 mg every 48 h
≤10
- Treatment
- 30 mg once
- Prophylaxis
- 30 mg once, repeat after 7 days
Haemodialysis
- Treatment
- 30 mg once, then 30 mg after each session
- Prophylaxis
- 30 mg once, then after every second session
Peritoneal dialysis
- Treatment
- 30 mg once
- Prophylaxis
- 30 mg once, repeat after 7 days
Haemofiltration 1–1.8 L/h
- Treatment
- 30 mg OD
- Prophylaxis
- 30 mg every 48 h
Haemofiltration 1.9–3.6 L/h
- Treatment
- 30 mg BD
- Prophylaxis
- 30 mg OD
Haemofiltration >3.6 L/h
- Treatment
- 75 mg BD
- Prophylaxis
- 75 mg OD
| CrCl (mL/min) | Treatment | Prophylaxis |
|---|---|---|
| >60 | 75 mg BD | 75 mg OD |
| 31–60 | 30 mg BD | 30 mg OD |
| 11–30 | 30 mg OD | 30 mg every 48 h |
| ≤10 | 30 mg once | 30 mg once, repeat after 7 days |
| Haemodialysis | 30 mg once, then 30 mg after each session | 30 mg once, then after every second session |
| Peritoneal dialysis | 30 mg once | 30 mg once, repeat after 7 days |
| Haemofiltration 1–1.8 L/h | 30 mg OD | 30 mg every 48 h |
| Haemofiltration 1.9–3.6 L/h | 30 mg BD | 30 mg OD |
| Haemofiltration >3.6 L/h | 75 mg BD | 75 mg OD |
🛡️ Prophylaxis
- Consider for asymptomatic household or residential close contacts at extremely high risk (85 or over, or any age with several major risk factors) who are not covered by vaccine: vaccine mismatch, or vaccinated less than 14 days ago.
- Outbreak, after a public health risk assessment and regardless of vaccine: on a hospital ward, at-risk patients only. In a nursing home, may be considered for all exposed residents on affected units.
- Pregnant, or up to 2 weeks after delivery or pregnancy loss: follow the HSE pregnancy influenza guidance, not this section.
- Previously healthy contacts: no prophylaxis. Stop it if another virus (such as RSV) is found.
- Contact of an oseltamivir-resistant case: no prophylaxis. Monitor and treat early with specialist advice.
🚨 Cautions
- Starting oseltamivir for the first time after ICU admission is not routinely recommended (interim HSE position). Continue it if already started. Discuss with ICU and micro.
- Poor response or poor GI absorption: discuss IV zanamivir with micro or ID. Severely immunocompromised with H1N1pdm09: zanamivir first line may be considered.
- Do not interrupt treatment. If resistance is suspected, switch without waiting for the result.
- Pregnancy: treat severe influenza with oseltamivir, no dose change. Follow the HSE pregnancy influenza guidance.
- Nausea, vomiting and headache are common: give with food. Neuropsychiatric events are reported, mostly in children and teenagers.
- Only 75 mg capsules and the 6 mg/mL suspension are available in Ireland: give 30 mg doses as 5 mL suspension. Cannot swallow: 75 mg is 12.5 mL, or pharmacy can make a suspension from capsules.
External resources
Educational reference only. Medical disclaimer